These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 24090457

  • 1. Bone marrow suppression or active proliferation? An analysis of neutropenia after pegylated interferon treatment of patients with chronic hepatitis C.
    Liu YL, Du XF, Chen XY, Ma LN, Guo DD, Lu JF, Cao ZH, Zhang YH.
    Scand J Infect Dis; 2013 Dec; 45(12):939-43. PubMed ID: 24090457
    [Abstract] [Full Text] [Related]

  • 2. Interferon-α suppressed granulocyte colony stimulating factor production is reversed by CL097, a TLR7/8 agonist.
    Tajuddin T, Ryan EJ, Norris S, Hegarty JE, O'Farrelly C.
    J Gastroenterol Hepatol; 2010 Dec; 25(12):1883-90. PubMed ID: 21092001
    [Abstract] [Full Text] [Related]

  • 3. Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy.
    Koirala J, Gandotra SD, Rao S, Sangwan G, Mushtaq A, Htwe TH, Adamski A, Blessman D, Khardori NM.
    J Viral Hepat; 2007 Nov; 14(11):782-7. PubMed ID: 17927614
    [Abstract] [Full Text] [Related]

  • 4. Defective synthesis of granulocyte-colony stimulating factor in pegylated interferon-alpha treated chronic hepatitis C patients with declining leukocyte counts.
    Durante-Mangoni E, Iardino P, Utili R, Adinolfi LE, Ruggiero G.
    Antivir Ther; 2006 Nov; 11(5):637-40. PubMed ID: 16964833
    [Abstract] [Full Text] [Related]

  • 5. Incidence and severity of infections according to the development of neutropenia during combined therapy with pegylated interferon-alpha2a plus ribavirin in chronic hepatitis C infection.
    Juarez-Navarro A, Vera-de-León L, Navarro JM, Chirino-Sprung R, Díaz-Hernandez M, Casillas-Davila L, Dehesa-Violante M.
    Methods Find Exp Clin Pharmacol; 2005 Jun; 27(5):317-22. PubMed ID: 16082419
    [Abstract] [Full Text] [Related]

  • 6. Treatment with PEG-interferon and ribavirin for chronic hepatitis C increases neutrophil and monocyte chemotaxis.
    Giorgini A, Capsoni F, Podda M, Lleó A, Battezzati PM, Ongari AM, Selmi C, Benetti A, Malinverno F, Rossaro L, Gershwin ME, Zuin M.
    Ann N Y Acad Sci; 2009 Sep; 1173():847-57. PubMed ID: 19758237
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Granulocyte colony-stimulating factor for hepatitis C therapy-associated neutropenia: systematic review and economic evaluation.
    Tandon P, Doucette K, Fassbender K, Vandermeer B, Durec T, Dryden DM.
    J Viral Hepat; 2011 Jul; 18(7):e381-93. PubMed ID: 21692951
    [Abstract] [Full Text] [Related]

  • 9. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
    Antonini MG, Babudieri S, Maida I, Baiguera C, Zanini B, Fenu L, Dettori G, Manno D, Mura MS, Carosi G, Puoti M.
    Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Granulocyte colony stimulating factor in HCV genotype-1 patients who develop Peg-IFN-alpha2b related severe neutropenia: a preliminary report on treatment, safety and efficacy.
    Koskinas J, Zacharakis G, Sidiropoulos J, Elefsiniotis J, Savvas S, Kotsiou S, Kountouras D, Schina M, Kostopoulos P, Archimandritis A.
    J Med Virol; 2009 May; 81(5):848-52. PubMed ID: 19319942
    [Abstract] [Full Text] [Related]

  • 15. Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation?
    Puoti M, Babudieri S, Rezza G, Viale P, Antonini MG, Maida I, Rossi S, Zanini B, Putzolu V, Fenu L, Baiguera C, Sassu S, Carosi G, Mura MS.
    Antivir Ther; 2004 Aug; 9(4):627-30. PubMed ID: 15456094
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Pegylated interferon and ribavirin associated retinopathy in patients with hepatitis C].
    Burgueño-Montañés C, Pérez-Álvarez R.
    Arch Soc Esp Oftalmol; 2011 Jun; 86(6):193-5. PubMed ID: 21767697
    [Abstract] [Full Text] [Related]

  • 19. Feasibility of pegylated interferon and ribavirin in hepatitis C-related cirrhosis with neutropenia or thrombocytopenia.
    Iacobellis A, Cozzolongo R, Minerva N, Valvano MR, Niro GA, Fontana R, Palmieri O, Ippolito A, Andriulli A.
    Dig Liver Dis; 2014 Jul; 46(7):621-4. PubMed ID: 24675038
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.